Clinical trial

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

NCT03523338

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Apalutamide Normalized identity: apalutamideView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention ADT (Standard of Care) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

Design: EXPANDED_ACCESS · Status: NO LONGER AVAILABLE · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNO_LONGER_AVAILABLE

Study typeEXPANDED_ACCESS

Start dateUnknown

PhaseN/A

Conditions

Prostatic Neoplasmsunresolved

Interventions

ApalutamideDRUG · verified · RxNorm: apalutamide

ADT (Standard of Care)DRUG

Sponsors & collaborators

Aragon Pharmaceuticals, Inc.lead sponsor

Mapped research locations

São PauloBrazil3 Rio de JaneiroBrazil1 MonterreyMexico1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03523338 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.